Tumors
Conditions
Brief summary
To learn about the symptoms and changes our patients experience while receiving treatment for sinonasal or nasopharyngeal cancer
Detailed description
Objectives: * To estimate the prevalence and severity of adverse and functional outcomes in survivors of benign and malignant paranasal sinus, nasopharynx and skull base tumors. * To estimate the prevalence of health promotion behaviors during skull base tumor survivorship * To identify possible mediators or predictors of survivorship outcomes and health behaviors in survivors of skull base tumors. * To develop a database of demographic, clinicopathologic, recurrence, survival, functional and patient reported outcomes (PROS) for patients with benign and malignant paranasal sinus, nasopharyngeal and skull base tumors. * To assess the utility and limitations of PROs in evaluating functional impairments and symptom burden in skull base patients.
Interventions
BEHAVIORALStandard of Care
Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
Sponsors
M.D. Anderson Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Previously untreated patients with or suspected to have sinonasal malignancy or nasopharyngeal malignancy diagnosis based on either outside pathology report or MD Anderson pathology report. 2. Age ≥ 18 years 3. Plan to obtain the majority of treatment at MDACC including surgery and radiotherapy 4. Ability to understand and willingness to sign written informed consent
Exclusion criteria
1. History of the previous solid or liquid malignancies, apart from skin cancers treated with local therapy. 2. Existing neurocognitive impairment that is not the result of sinonasal and nasopharyngeal cancers or is treatment. 3. Previous treatment for sinonasal or nasopharyngeal carcinomas, apart from biopsy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN) | through study completion; an average of 1 year | MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN) is a disease specific PRO instrument validated for patients with head and neck cancer. It is the most commonly utilized instrument in the head and neck cancer population, of which sinonasal and nasopharyngeal tumors are disease subsites. Score scale from 0 (symptom has been present) to 10 (the symptom was as bad as you can imagine it could be) |
Countries
United States
Contacts
CONTACTShirley Su, MBBS
PRINCIPAL_INVESTIGATORShirley Su, MBBS
M.D. Anderson Cancer Center
Outcome results
None listed